NDUFA13 and breast carcinoma: In particular, ferroptosis pathway status was significantly associated with clinical outcomes and intra-tumoral heterogeneity in breast cancer patients, as NDUFA13 expression was identified as a positive biomarker for activating the ferroptosis pathway in breast cancer patients (Li Y. et al., 2022).